← Oncology Approval Tracker

FDA DECISION ·

Keytruda + pemetrexed + platinum

pembrolizumab with pemetrexed and platinum chemotherapy · Merck

FDA approvalNew or expanded indicationMalignant pleural mesothelioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma with pembrolizumab, pemetrexed and platinum chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The decision adds a chemoimmunotherapy option for advanced pleural mesothelioma alongside other regimen choices.

What research teams should watch

Ensure pathology subtype and baseline imaging are available, and align pleural tumor measurements and supportive medication schedules.

PRIMARY RECORDS

Sources